These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 21403668)

  • 21. Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?
    Howard LE; De Hoedt AM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Divers CH; Valderrama A; Freedland SJ
    Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):380-384. PubMed ID: 27377207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007).
    Yong M; Jensen AÖ; Jacobsen JB; Nørgaard M; Fryzek JP; Sørensen HT
    Breast Cancer Res Treat; 2011 Sep; 129(2):495-503. PubMed ID: 21461730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment disparities for disabled medicare beneficiaries with stage I non-small cell lung cancer.
    Iezzoni LI; Ngo LH; Li D; Roetzheim RG; Drews RE; McCarthy EP
    Arch Phys Med Rehabil; 2008 Apr; 89(4):595-601. PubMed ID: 18373987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of skeletal-related events and mortality in men with metastatic, castration-resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Tablazon IL; Howard LE; De Hoedt AM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Freedland SJ; Williams SB
    Cancer; 2019 Nov; 125(22):4003-4010. PubMed ID: 31390061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate cancer treatment and ten-year survival among group/staff HMO and fee-for-service Medicare patients.
    Potosky AL; Merrill RM; Riley GF; Taplin SH; Barlow W; Fireman BH; Lubitz JD
    Health Serv Res; 1999 Jun; 34(2):525-46. PubMed ID: 10357289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease.
    Berruti A; Tucci M; Mosca A; Tarabuzzi R; Gorzegno G; Terrone C; Vana F; Lamanna G; Tampellini M; Porpiglia F; Angeli A; Scarpa RM; Dogliotti L
    Br J Cancer; 2005 Sep; 93(6):633-8. PubMed ID: 16222309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
    Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
    Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era.
    Carter CA; Donahue T; Sun L; Wu H; McLeod DG; Amling C; Lance R; Foley J; Sexton W; Kusuda L; Chung A; Soderdahl D; Jackmaan S; Moul JW
    J Clin Oncol; 2003 Nov; 21(21):4001-8. PubMed ID: 14581423
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases.
    Hagiwara M; Delea TE; Saville MW; Chung K
    Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):23-7. PubMed ID: 23146970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
    J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
    Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
    J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer.
    Yong C; Onukwugha E; Mullins CD
    Curr Opin Oncol; 2014 May; 26(3):274-83. PubMed ID: 24626126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer.
    Gandaglia G; Karakiewicz PI; Briganti A; Passoni NM; Schiffmann J; Trudeau V; Graefen M; Montorsi F; Sun M
    Eur Urol; 2015 Aug; 68(2):325-34. PubMed ID: 25108577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit.
    van Leeuwen PJ; Connolly D; Gavin A; Roobol MJ; Black A; Bangma CH; Schröder FH
    Eur J Cancer; 2010 Jan; 46(2):377-83. PubMed ID: 19804966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lactate dehydrogenase is a prognostic indicator for prostate cancer patients with bone metastasis.
    Naruse K; Yamada Y; Aoki S; Taki T; Nakamura K; Tobiume M; Zennami K; Katsuda R; Sai S; Nishio Y; Inoue Y; Noguchi H; Hondai N
    Hinyokika Kiyo; 2007 May; 53(5):287-92. PubMed ID: 17561711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of multivitamins and prostate cancer mortality in a large cohort of US men.
    Stevens VL; McCullough ML; Diver WR; Rodriguez C; Jacobs EJ; Thun MJ; Calle EE
    Cancer Causes Control; 2005 Aug; 16(6):643-50. PubMed ID: 16049802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer.
    Smith MR; Lee WC; Brandman J; Wang Q; Botteman M; Pashos CL
    J Clin Oncol; 2005 Nov; 23(31):7897-903. PubMed ID: 16258089
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recreational physical activity and prostate cancer risk (United States).
    Littman AJ; Kristal AR; White E
    Cancer Causes Control; 2006 Aug; 17(6):831-41. PubMed ID: 16783611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The burden of depression in prostate cancer.
    Jayadevappa R; Malkowicz SB; Chhatre S; Johnson JC; Gallo JJ
    Psychooncology; 2012 Dec; 21(12):1338-45. PubMed ID: 21837637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of statins and the risk of death in patients with prostate cancer.
    Yu O; Eberg M; Benayoun S; Aprikian A; Batist G; Suissa S; Azoulay L
    J Clin Oncol; 2014 Jan; 32(1):5-11. PubMed ID: 24190110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.